The respiratory tract surface is protected from inhaled pathogens by a secreted layer of mucus that is rich in mucin glycoproteins. Disrupted mucus production is a cardinal feature of chronic respiratory diseases but how this alteration affect interactions between mucins and pathogens is complex and poorly understood. Here, we identify a central and unexpected role for the major airway mucin MUC5AC in pathogenesis of virus-induced exacerbations of chronic obstructive pulmonary disease (COPD). Virus induction of MUC5AC is augmented in COPD compared to healthy subjects, is enhanced in frequent exacerbators and correlates with inflammation, symptom severity and secondary bacterial infection during exacerbation. MUC5AC is functionally related to inflammation as MUC5ACdeficient (Muc5ac-/-) mice had attenuated rhinovirus-induced airway inflammation whilst exogenous MUC5AC glycoprotein administration augmented virus-induced inflammatory responses and bacterial load. Mechanistically, MUC5AC-augmentation of rhinovirus-induced inflammation occurred through release of extracellular adenosine triphosphate (ATP). Therapeutic suppression of virus-induced MUC5AC release using an epidermal growth factor receptor (EGFR) inhibitor ameliorated exaggerated pro-inflammatory responses in a mouse COPD exacerbation model. Collectively, these studies demonstrate previously unrecognised pro-inflammatory effects of MUC5AC during infection and thus highlight a key unforeseen role in driving COPD exacerbation severity.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is an inflammatory airway disorder punctuated by acute exacerbations, frequently precipitated by rhinoviruses (RVs) 1, 2 .
Exacerbations are the major cause of morbidity and mortality in COPD 3, 4 and a greater understanding of the underlying pathophysiological mechanisms is urgently needed to facilitate development of new therapies to reduce the impact of these debilitating episodes.
Respiratory mucosal surfaces are continuously exposed to inhaled pathogens and a protective layer of secreted mucus that is rich in mucin glycoproteins acts as a first-line of defense against infection. Alterations in mucus secretion including enhancement of the major airway mucins MUC5AC and MUC5B are a cardinal feature of inflammatory airway COPD [5] [6] [7] . The complexity of interactions between mucins and pathogens and how the perturbations in mucin expression that occur in COPD affect infection susceptibility and subsequent exacerbation pathogenesis are poorly understood and it is not known whether inhibition of mucus production would be beneficial or harmful in this context.
Animal studies have revealed critical roles for MUC5AC and MUC5B in anti-viral and antibacterial host-defense 8, 9 suggesting that use of anti-secretory therapies may compromise a protective role for mucins during exacerbations. Conversely, mucin levels are higher in COPD patients who experience frequent exacerbations 7 raising speculation for a possible functional role in exacerbation pathogenesis. Additionally, accumulation of small airway mucus-containing inflammatory exudates has been shown to be associated with early death in patients with COPD treated by lung volume reduction surgery 10 and airway MUC5AC mediates airway hyperresponsiveness 11 and is over-expressed in cases of fatal asthma 12 , suggesting that mucins could be a marker or cause of adverse outcome. These studies would support the opposing view that targeted suppression of mucins during exacerbations might provide desirable improvement in outcomes.
Here, using human studies in combination with functional experiments in mouse models, we identify a central and unforeseen role for MUC5AC in amplifying virus-induced airway inflammation and driving subsequent exacerbation severity in COPD. We identify a mechanism for augmentation of virus-induced inflammation by MUC5AC through release of extracellular adenosine triphosphate (ATP) and show that therapeutic suppression of virusinduced MUC5AC release using an epidermal growth factor receptor (EGFR) inhibitor ameliorates exaggerated pro-inflammatory responses in a mouse COPD exacerbation model. Our studies are the first to implicate MUC5AC as a key functional driver of COPD exacerbation pathogenesis and indicate that selective therapeutic inhibition of this mucin could lead to improved clinical outcomes.
RESULTS

MUC5AC is induced during naturally-occurring COPD exacerbations and enhanced in frequent exacerbators
We initially evaluated the expression of the major mucin glycoproteins MUC5AC and MUC5B in sputum samples taken from COPD patients during virus-associated naturallyoccurring exacerbations (Fig.1a ) in our community-based cohort study. A total of 27 exacerbations were reported, of which 18 exacerbations (67%) were associated with positive virus detection by PCR of sputum samples (rhinovirus n=11, coronavirus n=4, RSV n=2, influenza n=1) as previously reported. 13 These 18 virus-positive exacerbation samples were used for analyses (see Table 1 for the clinical characteristics of the subjects reporting these 18 exacerbations). Significant increases from baseline were observed for sputum supernatant MUC5AC protein concentrations at exacerbation presentation and at 2 weeks during exacerbation with no significant increase observed for MUC5B protein (Fig.1b ).
During exacerbation, peak concentrations of MUC5AC (i.e. maximal concentrations detected during exacerbation) protein were increased compared to baseline with no significant increase observed for MUC5B ( Fig.1c ). Frequent exacerbators (patients with a history of >2 exacerbations in the preceding year) had increased sputum MUC5AC concentrations at exacerbation presentation and at 2 weeks during exacerbation compared with infrequent exacerbators (0 or 1 exacerbations in the preceding year), with no significant differences observed for MUC5B ( Fig. 1d) .
Given that ELISA-based quantification of sputum mucins may be influenced by proteases present in this sample type 14 , we further confirmed our observations using quantitative PCR to measure mucin expression in RNA extracted from sputum cells from the same subjects.
In keeping with our findings for mucin proteins, we also observed that sputum MUC5AC mRNA was significantly increased at exacerbation onset with no increase observed for MUC5B mRNA (Fig 1e) , providing additional evidence that MUC5AC is the major induced mucin during naturally-occurring COPD exacerbations.
COPD is associated with augmented MUC5AC responses to experimental rhinovirus challenge
We next utilised our previous human RV challenge studies 1, 15 to more accurately define the temporal dynamics of mucin expression during RV-induced COPD exacerbations ( Fig.2a and Supplementary Fig.1a )(Clinical characteristics of these subjects are shown in Table 2 ). A significant increase in sputum MUC5AC from baseline was observed in RV-infected COPD subjects at day 3 post-infection with no increase observed in healthy control subjects ( Fig.2b ). MUC5AC was increased in patients with COPD versus healthy controls on days 3, 9 and 12 post-infection ( Fig.2b ). There was no significant change in MUC5B from baseline at any time point in patients with COPD or healthy controls and no difference in MUC5B was observed between these two groups during infection (Supplementary Fig.1b ). MUC5AC peak concentrations were increased in patients with COPD compared to baseline with no significant change observed in healthy individuals and peak MUC5AC concentrations were higher in COPD compared to healthy subjects ( Fig.2c ). MUC5B peak concentrations were increased in both groups of volunteers when compared to baseline with no significant difference observed between the two groups ( Supplementary Fig.1c ).
RV-induced MUC5AC is related to COPD exacerbation severity
Having characterised the expression of mucins during exacerbation, and noting that MUC5AC induction occurs at day 3, a time-point that precedes peak airway inflammation, which occurs between days 9 and 15 post-infection 1, 15 , we next sought to assess relationships between MUC5AC responses and inflammatory responses to infection in our human experimental challenge model. We observed highly significant positive correlations between sputum MUC5AC and cellular airway inflammation (total cell counts and neutrophil counts, Fig.2d ) and between MUC5AC and concentrations of soluble mediators of inflammation including CXCL8/IL-8, CXCL10/IP-10, IL-1b, GM-CSF IL-6 and TNF ( Fig.2d ).
Since virus replication acts as a driver for airway inflammation 1, 15 , we also examined relationships between sputum mucins and virus load and found a positive correlation between sputum MUC5AC and sputum virus load ( Fig.2e ).
We have previously reported that rhinovirus infection induces secondary bacterial infection in COPD through neutrophil elastase cleaving the anti-microbial peptides (AMPs) secretory leucocyte proteinase inhibitor (SLPI) and elafin to promote bacterial growth 16 . We found that sputum MUC5AC correlated positively with sputum neutrophil elastase concentrations during infection ( Fig.2f ) and negatively with the change from baseline in sputum SLPI and elafin concentrations during infection ( Fig.2g ), consistent with greater MUC5AC levels during infection being associated with greater induction of neutrophil elastase, and consequent increased degradation of these AMPs. COPD patients with positive bacterial cultures during RV infection also had higher concentrations of sputum MUC5AC during infection and sputum MUC5AC concentrations correlated with bacterial loads determined by 16S qPCR (Fig.2h ). To confirm these latter findings observed in the rhinovirus challenge model, we performed similar analyses in the naturally occurring COPD exacerbation study and found that sputum MUC5AC concentrations during virus-induced exacerbations also correlated with bacterial loads in the 2 week sample during exacerbation, as the peak of secondary bacterial infections occurs around 2 weeks after virus infection 16 (Supplementary   Fig.2a ). Although not induced during infection at any time point assessed, similar analyses were carried out for MUC5B. However, in contrast to MUC5AC, MUC5B did not significantly correlate with any inflammatory marker except GM-CSF ( Supplementary Fig.1d) . Similarly, there were no significant correlations of MUC5B with virus load (Supplementary Fig.1e ), and changes from baseline in antimicrobial peptide concentrations ( Supplementary Fig. 1f) or bacterial loads during experimental ( Supplementary Fig.1g ) or naturally-occurring ( Supplementary Fig.2b ) COPD exacerbation.
Pro-inflammatory cytokines and cellular airway inflammation are believed to contribute to duration and severity of RV-induced asthma exacerbations 17, 18 and secondary bacterial infection is also associated with greater exacerbation severity in RV-induced COPD exacerbations 16 . Having observed associations between concentrations of MUC5AC and airway inflammation, virus load and secondary bacterial infections, we next determined whether airway mucins during exacerbations were related to clinical outcomes during exacerbation. We observed that sputum MUC5AC concentrations correlated with both upper and lower respiratory tract symptom scores ( Fig.2i ) with no significant correlations observed for MUC5B ( Supplementary Fig.1h ). Since chronic mucus hypersecretion is associated with long term FEV 1 decline 19 , we also hypothesized that the amplified induction of MUC5AC during RV infection would be related to acute lung function changes during COPD exacerbation. In experimental RV-induced COPD exacerbations, sputum MUC5AC concentrations correlated negatively with the maximal fall from baseline in peak expiratory flow during exacerbation ( Fig. 2j ) with no such correlation observed for MUC5B ( Supplementary Fig.1i ).
To confirm these findings, we additionally measured MUC5AC in an alternative sample type, bronchoalveolar lavage (BAL), as subjects in the experimental infection study also underwent bronchoscopy at baseline and day 7 after RV infection. BAL MUC5AC protein was similarly increased in COPD subjects versus healthy non-smokers with no difference observed for MUC5B ( Supplementary Fig 3) .
Combined, these observations confirmed that MUC5AC is the major induced mucin during human virus-induced COPD exacerbations and that concentrations of MUC5AC correlate with inflammation, virus load, secondary bacterial infections and clinical measures of exacerbation severity.
Muc5ac-/-mice have attenuated inflammatory responses to RV infection
We next sought to further understand the functional importance of MUC5AC during RV infection using mouse models in which cause and effect relationships can readily be assessed. Mice with gene-targeted deletion of Muc5ac (Muc5ac-/-) ( Fig.3a ) had attenuated cellular airway inflammation (BAL total cell counts and neutrophil numbers; Fig.3b ) and reduced concentrations of the neutrophil chemokines CXCL1/KC and CXCL2/MIP-2 ( Fig.   3c ) following RV infection compared to wild-type controls. BAL concentrations of the proinflammatory cytokines IL-1b, IL-6 and TNF were also reduced in RV-infected Muc5ac-/mice compared to wild-type controls (Fig. 3d) . The pro-inflammatory effects of MUC5AC were not mediated via interference with antiviral immune responses or virus control as Muc5ac-/-mice and wild type controls had similar levels of IFN-α and IFN-l2/3 protein in BAL and no difference in lung virus loads ( Supplementary Fig 4a-d) .These data indicated that MUC5AC is functionally related to airway inflammatory responses during RV infection.
Exogenous MUC5AC protein augments RV-induced airway inflammation and increases bacterial loads in mice
To further confirm a functional role for MUC5AC in RV-induced inflammation and exacerbation severity, we evaluated the in vivo effects of exogenous MUC5AC glycoprotein in the mouse model of RV infection ( Fig.4a ). Exogenous MUC5AC administration alone had no effect on BAL inflammatory cell numbers ( Fig.4b ) or pro-inflammatory chemokine or cytokine concentrations ( Fig.4c&d ) but MUC5AC administration (0.5mg/mL) enhanced RVinduced airway inflammation including increased total cell and neutrophil numbers (Fig. 4b) ,
and increased BAL concentrations of the pro-inflammatory chemokines CXCL1/KC, CXCL2/MIP-2 and CCL5/RANTES and cytokines IL-1b, IL-6 and TNF ( Fig.4c&d ).
Conversely, administration of MUC5B protein or a control polymer solution of agarose/dextran at the same concentration (0.5mg/mL) had no effect on inflammation, either alone or when administered in combination with RV infection in mice. (Supplementary Fig   5) Consistent with our hypothesis that MUC5AC drives neutrophil elastase-mediated cleavage of AMPs and subsequently increases bacterial loads, we also observed that exogenous MUC5AC increased RV-induction of neutrophil elastase ( Fig.4e ), suppressed RV-induction of SLPI and augmented lung bacterial loads during virus infection ( Fig.4f ). Similar to what was observed with knockout mice, exogenous Muc5ac also had no effect on induction of
IFN-α or IFN-l2/3 nor lung virus loads in RV-infected mice (Supplementary Fig4e-h).
MUC5AC exerts pro-inflammatory effects via extracellular ATP
We next sought to understand how MUC5AC amplifies inflammation during RV infection.
Given our prior observations that Muc5ac deletion was anti-inflammatory, while augmentation with exogenous MUC5AC protein in mice had broad pro-inflammatory effects, we reasoned that this mucin could be mediating its effects via a danger signal that promotes inflammatory mediator release and cell recruitment. A previous study demonstrated that supernatants of mucopurulent material from subjects with cystic fibrosis can induce epithelial release of extracellular adenosine triphosphate (ATP) 20 , a well-recognised promoter of inflammation 21 that is also virus-inducible 22 . We therefore hypothesised that MUC5AC exerts its pro-inflammatory effects during RV infection via induction of extracellular ATP and examined the effect of ATP neutralisation using the ATP-hydrolysing enzyme apyrase in exogenous MUC5AC-treated RV-infected mice (Fig 5a) . Exogenous MUC5AC protein administration augmented BAL concentrations of ATP in RV-infected mice, an effect that was abrogated by instillation of apyrase (Fig 5b) . Apyrase administration also suppressed exogenous MUC5AC-mediated increases in airway inflammation during RV infection including BAL total cells and neutrophils ( Fig. 5c ), inflammatory chemokines CXCL1/KC, CXCL2/MIP-2 and CCL5/RANTES ( Fig. 5d ) and pro-inflammatory cytokines TNF and IL-1b ( Fig. 5e ). Apyrase also prevented the exogenous MUC5AC-mediated increase in neutrophil elastase, reversed the MUC5AC-mediated suppression of SLPI and suppressed MUC5ACmediated increased bacterial loads in RV-infected mice (Fig 5f-g) . Apyrase-mediated reversal of pro-inflammatory effects of MUC5AC did not occur via interference with antiviral immune responses or virus control, as we also observed no effect of apyrase on RVinduction of IFN-α, IFN-l2/3 (Supplementary Fig.6a-c Fig.6d ).
) or lung virus loads (Supplementary
These data confirmed that MUC5AC exerts its pro-inflammatory effects during RV infection through MUC5AC-mediated induction of release of extracellular ATP.
Therapeutic inhibition of MUC5AC induction by RV protects against RV-induced exacerbation in a mouse model of COPD-like disease
Having confirmed the functional importance of MUC5AC in RV-induced airway inflammation, we next hypothesised that inhibiting RV-induction of this glycoprotein would have beneficial effects during RV-induced COPD exacerbations. Rhinoviruses induce MUC5AC expression through EGFR signalling 23 . We therefore assessed the effect of EGFR inhibition in a mouse model of elastase-induced emphysema combined with RV-infection in which many features of human COPD exacerbation including mucus hypersecretion are recapitulated 24 .
Administration of the EGFR inhibitor AG1478 prior to RV infection in elastase treated mice ( Fig.6a ) suppressed RV-induction of lung Muc5ac mRNA, BAL MUC5AC protein ( Fig.6b) and suppressed airway epithelial cell mucus staining in lung sections ( Fig. 6c , control groups are shown in Supplementary Fig. 7) . AG1478 had no effect on BAL MUC5B protein concentrations ( Supplementary Fig.8a&b ). AG1478 administration in elastase-treated mice also suppressed RV-induction of BAL cellular airway inflammation ( Fig.6d ), as well as chemokines CXCL1/KC, CXCL2/MIP-2 and CCL5/RANTES ( Fig.6e ), pro-inflammatory cytokines IL-1b, IL-6, TNF and GM-CSF ( Fig.6f ) and neutrophil elastase ( Fig.6g ). AG1478 treatment in elastase-treated RV-infected mice also enhanced BAL SLPI levels and reduced pulmonary bacterial loads ( Fig.6h ). Finally, elastase and AG1478-treated RV-infected mice had reduced AHR to methacholine challenge compared to elastase and vehicle treated, RV infected controls ( Fig.6i) These anti-inflammatory effects of AG1478 were not mediated via interference with antiviral immune responses or virus control, as we also observed no effect of AG1478 on RVinduction of IFN-α, IFN-l2/3 ( Supplementary Fig.8c&d ) or lung virus loads.
( Supplementary Fig.8e ).
DISCUSSION
The mechanisms underlying virus-induced exacerbations in COPD and the factors that drive inflammation and clinical severity during these episodes are poorly understood. Here, we provide insight into the role that the major airway mucin glycoprotein MUC5AC plays in the biology of these episodes. Using a combination of human and mouse models of rhinovirus infection in COPD, we demonstrate a novel central role of virus-induced MUC5AC in driving COPD exacerbation severity through amplification of airway inflammation, findings that open up new opportunities for targeting MUC5AC therapeutically. We indicate a mechanism for MUC5AC augmentation of RV-induced inflammation via release of extracellular ATP.
We show here, that MUC5AC is selectively induced during virus-induced COPD exacerbations and increased compared to virus-infected healthy subjects. By contrast, MUC5B was not induced above baseline and did not differ between COPD and control subjects at any timepoint, indicating that MUC5AC is the major induced mucin during exacerbations. We also found positive correlations between MUC5AC and a range of inflammatory markers. Since airway inflammation is enhanced in COPD exacerbations and believed to contribute to duration and severity of RV induced illnesses 17, 18 we also determined the relationship between MUC5AC and exacerbation severity, finding positive correlations with virus loads, symptom scores and acute lung function decline. MUC5AC is one of the major glycoprotein components of airway mucus and it is therefore unsurprising that its expression during virus infection correlates with lower respiratory symptom scores which comprise an assessment of sputum production. The correlation of MUC5AC with PEF decline can be explained by the fact that greater mucus production is likely to contribute directly to airway obstruction during exacerbation. Our findings in this acute human infection model are in keeping with clinical studies that have reported the association of symptomdefined chronic mucus hypersecretion phenotype with airflow limitation and FEV 1 decline 19, 25 and an animal study showing that genetic deletion of Muc5ac reduces mucus occlusion and improves lung function in models of allergic airway inflammation 11 .
We have previously reported that experimental RV infection in patients with COPD is associated with increased frequency of secondary bacterial infection compared to healthy subjects 16, 26 via a mechanism of virus-induced neutrophil elastase-mediated cleavage of the anti-microbial peptides SLPI and elafin. The positive correlation of sputum MUC5AC with neutrophil numbers, neutrophil elastase concentrations and secondary bacterial infection and negative correlation with SLPI and elafin levels observed in the current study suggests that increased MUC5AC could be one mechanism contributing to enhanced neutrophilic airway inflammation, greater neutrophil elastase levels and thus greater risk of development of secondary bacterial infections. Siegel et al previously demonstrated reduced secondary pneumococcal growth following influenza infection in Muc5ac-/-mice 27 , an effect mediated by reduced provision of mucin-derived nutrients for bacterial growth in Muc5ac-/-mice, indicating that MUC5AC may be an important promoter of secondary bacterial infection via more than one mechanism. Combined with our findings in a clinically relevant human model, this highlights inhibition of MUC5AC as a potential target for reducing secondary bacterial infection in COPD.
A recent study by Kesimer et al showed that total mucin concentrations in sputum at stable state were higher in COPD patients who experienced frequent exacerbations 7 . Previous studies have also reported chronic mucus hypersecretion to be associated with increased exacerbation frequency 28, 29 and mortality risk related to pulmonary infection 30 . Here, we identify that frequent exacerbators also have enhanced sputum MUC5AC concentrations during exacerbation. Underlying mechanisms involved in the frequent exacerbator phenotype are poorly characterised, but our data raise speculation that these patients may have exaggerated mucin responses to infection potentially leading to enhanced airway inflammation and increased symptoms.
The human experimental challenge model facilitates sequential sampling at precisely defined time points during the course of infection and allows evaluation of the temporal relationship between variables. We observed that MUC5AC induction peaked early at day 3 in the time course of these RV-induced COPD exacerbations, preceding airway inflammation which peaks between day 9 and day 15 post-infection 1, 15 . Given the strong positive correlations observed between MUC5AC and these parameters in the current study, we Exogenous MUC5AC also enhanced rhinovirus-induction of neutrophil elastase, suppressed SLPI production and increased pulmonary bacterial loads, further confirming a role for
MUC5AC in inhibiting anti-bacterial responses during virus infection. A previous study by
Ehre et al evaluated responses to influenza infection in a transgenic Muc5ac overexpressing mouse strain and showed reduced viral titres and attenuated neutrophilic inflammation in this model 9 . This contrasts our findings using exogenous MUC5AC administration where there was no effect on virus loads and MUC5AC enhanced virus-induced inflammation. The transgenic strain employed by Ehre et al was associated with ~18-fold increase in airway MUC5AC levels 9 . This level of augmentation greatly exceeds the increases observed in our human analyses where a ~2-fold increase was observed in stable state levels of MUC5AC in COPD versus healthy subjects and ~2-to 3-fold increase was observed from baseline to exacerbation. The concentrations of exogenous MUC5AC protein administered in our animal experiments (0.25-0.5mg/mL) were ~ 1.5-3.5 fold higher than the baseline MUC5AC protein concentrations we measured in the mouse airway (~150µg/mL) and are therefore more likely to be physiologically relevant to human exacerbation. Further, the effect of MUC5AC in reducing virus loads at the much higher MUC5AC levels generated in the MUC5AC transgenic strain reported by Ehre et al may be virus-specific 9 . The authors reported that MUC5AC binds to the influenza virus receptor, α2,3-linked sialic acids in transgenic animals, consistent with a mechanism of influenza protection in vivo through impairment of efficient binding of virus to receptors on the bronchial epithelium leading to reduction in virus loads and consequently lesser inflammation. It is important to note that we used a non-human purified mucin protein in solution for our experiments which does not fully recapitulate the complex biophysical properties of mucin glycoprotein contained within endogenous airway mucus. We confirmed that the mucin preparation used was free of endotoxin and DNA but we cannot exclude that other mucin-bound proteins are present in the solution that may be contributing to the observed effects. Future validation of our findings using administration of human or mouse MUC5AC in similar mouse models is warranted, although extraction and purification of mucins from these sources is technically challenging and was not feasible for the current studies.
We identified a mechanism for amplification of rhinovirus-induced airway inflammation by MUC5AC through release of ATP, a danger signal that is released during infection and contributes to nucleotide receptor-dependent inflammatory responses 32 . This mechanism was suggested in a previous study that indicated that administration of sterile supernatants of mucopurulent material from subjects with cystic fibrosis can induce ATP release by human bronchial epithelial cells in vitro 20 . The role of ATP as a potential driver of airway inflammation in stable asthma and COPD is well recognised 33, 34 . Our findings, in models of infection, that neutralisation of pulmonary ATP levels abrogates MUC5AC enhancement of inflammation and secondary bacterial infection identifies a novel mechanism through which rhinovirus-induced mucin production enhances COPD exacerbation severity.
In addition to our observation that MUC5AC directly augments rhinovirus-induced airway inflammation, a number of previous studies have also demonstrated that inflammatory mediators such as neutrophil elastase and IL-1b can directly induce MUC5AC expression in lung epithelium 35 . We therefore speculate that mucin-induced airway inflammation might trigger further production of MUC5AC leading to a vicious cycle which contributes to enhanced airway inflammation and mucus hypersecretion to drive exacerbation severity in COPD. We thus hypothesised that early targeting of MUC5AC during rhinovirus infection might beneficially interrupt this cycle and evaluated the effect of upstream inhibition of rhinovirus-induction of MUC5AC using the EGFR inhibitor AG1478 in a COPD exacerbation mouse model. AG1478 suppressed rhinovirus-induced MUC5AC levels, accompanied by reduced airway inflammation, pro-inflammatory cytokines and chemokines, neutrophil elastase and AHR, as well as enhanced SLPI production and reduced bacterial loads in rhinovirus-infected elastase-treated mice. Importantly, AG1478 had no impact on anti-viral responses, or virus control, reassuringly indicating that therapies aimed at inhibiting MUC5AC production would not be expected to adversely affect anti-viral host-defence. Jing
et al recently reported in COPD airway epithelial cell cultures that administration of an EGFR
inhibitor had no effect on RV-induction of MUC5AC and concluded that EGFR does not play a role in promoting virus-induced mucin expression in COPD 36 . However, in this study, the authors examined mucin expression solely at a late timepoint (15 days) post RV infection and did not evaluate effects of the treatment on mucin expression at earlier timepoints nor subsequent effects on production of inflammatory mediators. The data from our human challenge model indicates that peak RV induction of MUC5AC occurs at a much earlier timepoint (3 days) and previous studies have shown that EGFR inhibition can attenuate the early induction of MUC5AC in RV-stimulated airway epithelial cell cultures 23, 37 Our data in a mouse model of COPD-like disease supports the assertion that the early production of MUC5AC in response to RV infection occurs through EGFR and is thus amenable to therapeutic inhibition. A previous study using an inhaled EGFR inhibitor in stable COPD reported more effective EGFR inhibition was related to greater decreases in epithelial mucin stores at higher doses, but this drug was poorly tolerated 38 . Systemic EGFR antagonists are now commonly used in lung adenocarcinoma therapy 39 . Our data in mice now provides justification for human studies to evaluate the role of repurposing these agents for use in COPD exacerbations to inhibit MUC5AC production which could theoretically suppress airway inflammation, reduce secondary bacterial infection and diminish exacerbation severity.
Mucins were quantified in our study using ELISA-based assays in historically collected sputum samples specifically within a separated sputum plug aliquot, as this was the sample type available to us. Sputum plugs from severe asthmatics have previously been shown to contain more MUC5AC than MUC5B 40 and this constituent likely contains more surface goblet cell derived mucin which may contribute to the differences observed between induction of these two mucins in our studies. However, we also observed increased RVinduced MUC5AC but not MUC5B in an alternative sample type (BAL) from COPD subjects versus healthy subjects, supporting our findings in sputum. There is also evidence to suggest that proteases within sputum samples can interfere with immunodetection of mucins 14 . Some studies have attempted to address this by using treatment with protease inhibitors shortly after sputum collection 6, 41 . We have previously reported, using samples from the same study, that neutrophil elastase is increased in COPD subjects compared to healthy subjects following virus challenge 16 . Given that we observed greater induction of MUC5AC protein in COPD subjects compared to healthy subjects, despite increased levels of proteases, this suggests that the actual difference between these two groups could be even more substantial than observed in our study. Additionally, our finding that sputum MUC5AC but not MUC5B mRNA expression was increased during naturally-occurring exacerbation (mirroring what was observed at the protein level) provides an additional confirmatory approach that would not be subject to these potential confounders. Other studies have used alternative semi-quantitative antibody-independent techniques 7,14,42 but it is unclear whether these approaches would have sufficient sensitivity to detect subtle changes in mucin expression during infection. The primary aim of the human component of our study was to study how mucin levels change during virus-induced exacerbations and our study was unique in that we had sequential sampling from individual patients during exacerbation with consistent methods used to measure mucins in all subjects.
In conclusion, we show that MUC5AC is the major induced mucin during virus infection in COPD and that virus-induced MUC5AC plays a central role in driving airway inflammation and exacerbation severity in COPD. Future development or repurposing of therapies that specifically target this component of mucus could lead to improved clinical outcomes.
METHODS
Experimental rhinovirus infection studies
Samples were analysed from subjects recruited to two experimental rhinovirus infection studies that have been published previously 1, 15, 16 . Samples from two groups were included in this analysis: COPD subjects (GOLD stage II, not using regular inhaled therapy) and healthy non-smokers. All subjects gave informed written consent and the protocol was approved by St Mary's NHS Trust Research Ethics Committee (study numbers 00/BA/459E and 07/H0712/138). Baseline samples of induced sputum and bronchoalveolar lavage (BAL), collected and processed as previously described 1 , were obtained when subjects had been free of COPD exacerbation/respiratory tract infection for at least 6 weeks, approximately 14 days prior to infection. Subjects were inoculated with rhinovirus-16 with samples collected on subsequent visits post-infection as described previously 1, 15 . Sputum from 14 subjects with COPD and 10 non-smoking healthy control subjects had complete remaining sample availability for the full time course from baseline to day 42 and were used for the present studies.. Daily diary cards of upper and lower respiratory tract symptom scores and peak expiratory flow (PEF) measurements were taken as previously described 1 .
The St. Mary's Hospital Naturally-occurring COPD exacerbation cohort
A cohort of 40 COPD subjects was recruited to a longitudinal study carried out at St. Mary's Hospital London between June 2011 and December 2013 investigating the pathogenesis of naturally-occurring exacerbations, as previously reported 43 . The subjects all had a clinical diagnosis of COPD that was confirmed with spirometry. Subjects of all grades of COPD severity were recruited and all treatments were permitted. All subjects gave informed written consent and the study protocol was approved by the East London Research Ethics Committee (Protocol number 11/LO/0229).
All subjects had an initial visit at baseline when clinically stable for clinical assessment, PEF and clinical sample collection including spontaneous or induced sputum, taken as previously described 1, 44 . Subjects reported to the study team when they developed symptoms of an upper respiratory tract infection or an increase in any of the symptoms of dyspnoea, cough and sputum volume or purulence and an exacerbation was defined using the East London cohort criteria 4 . Subjects were seen within 48 hours of onset of their symptoms for collection of samples and repeat visits were scheduled for two and six weeks after the initial exacerbation visit with clinical assessment, lung function and induced sputum repeated at these time-points. Viruses were detected in sputum by PCR, as described previously 1 .
Mouse models
Female mice (age 6-8 weeks) purchased from Charles River Laboratories on a C57BL/6 background were used for all wild-type animal studies. Muc5ac-/-mice were generated on a C57BL/6 background at the University of Colorado, as previously described 11 . Mice were housed in individually ventilated cages under specific pathogen-free conditions. All work was completed in accordance with UK Home office guidelines (Project licence PPL 70/7234). For evaluation of EGFR inhibitor in a COPD exacerbation model, as previously reported 24 , mice were treated intranasally under light isoflurane anaesthesia with 1.2 units of porcine pancreatic elastase (Merck, UK) to induce COPD-like changes. Ten days following elastase administration, as previously described 46 , mice were treated intraperitoneally with 50mg/kg of the EGFR inhibitor AG1478, 16 hours prior to intranasal infection with 50μL RV-A1 (2.5 x 10 6 TCID 50 ) or UV-inactivated RV-A1 control.
Measurement of cytokines, mucins and ATP
Cytokine protein levels in mouse BAL, human sputum supernatants or cell supernatants from in vitro experiments were assayed using commercial "duoset" enzyme-linked immunosorbent assay kits (R&D Systems, Abingdon, UK). The MesoScale Discovery (MSD) platform (Maryland, USA) was used to measure inflammatory mediators IL-1b, IL-6, TNF, CXCL8/IL-8, CXCL10/IP-10 and GM-CSF in sputum supernatants according to manufacturers' instructions as published previously 15 . Protein levels of human secretory leucocyte proteinase inhibitor (SLPI), elafin, neutrophil elastase, and all mouse BAL proteins were assayed using commercial ELISA assay kits, as previously described 16, 47 .
MUC5AC and MUC5B proteins in previously stored human sputum plugs or human/mouse BAL were measured after adhesion to a 96 well plate by allowing samples to evaporate at 37 o C overnight, using in-house assays as previously described 47 . For measurement of MUC5AC, the detection antibody used was biotinylated anti-MUC5AC (ThermoScientific, UK) at 400 ng/mL. For the MUC5B assay, detection antibody was mouse anti-MUC5B clone EH-Muc5ba, as previously described 48 . Bound anti-MUC5B antibody was detected with peroxidase-conjugated goat anti-mouse IgG (Sigma-Aldrich, UK). Mucins were quantified against the following standards: purified porcine MUC5AC, as previously described 45 and recombinant MUC5B protein (Caltag Medsystems, UK).
To measure ATP levels in mouse BAL supernatants, the ATPLite assay (Perkin Elmer) was used, according to manufacturer instructions but with the cell lysis step omitted, as previously described 34 .
RNA extraction, cDNA synthesis and quantitative PCR
For human studies, total RNA was extracted from sputum cells (RNeasy kit, Qiagen) and 2 µg was used for cDNA synthesis (Omniscript RT kit). For mouse models, total RNA was extracted from the right upper lobe of mouse lung and placed in RNA later, prior to RNA extraction and cDNA synthesis. Quantitative PCR (qPCR) was carried out using previously described specific primers and probes for human and mouse MUC5AC and MUC5B and rhinovirus RNA copy numbers 23, 47, 49 , and normalized to 18S rRNA.
DNA extraction and bacterial 16S quantitative PCR
DNA extraction from human sputum and mouse lung was performed using the FastDNA Spin Kit for Soil (MP Biomedicals, USA), following manufacturer instructions. Bead-beating was performed for two cycles of 30 seconds at 6800 rpm (Precellys, Bertin Technologies, France). 16S bacterial loads were measured using qPCR, as previously described 50 .
Statistical analyses
Data from human COPD studies were analysed using the Wilcoxon matched-pairs signed rank test or Mann-Witney U test. Correlations between datasets were examined using Spearman's rank correlation coefficient. For mouse experiments, animals were studied in group sizes of 5 mice with data shown representative of at least 2 independent experiments.
Data were analysed using one or two-way ANOVA with significant differences between groups assessed by Bonferroni's multiple comparison test. All statistics were performed using GraphPad Prism 6 software. Differences were considered significant when P<0.05. Supplementary Figure 1 : Airway MUC5B expression and correlation with inflammation and clinical parameters during experimental rhinovirus infection in COPD and healthy subjects. (a) Experimental outline. 14 subjects with COPD and 10 healthy control volunteers underwent sampling and analysis at baseline (~ 14d before RV-A16 inoculation) and at the indicated timepoints after RV-A16 infection. (b) Sputum MUC5B concentrations in COPD and healthy subjects at baseline, and after RV-A16 infection, measured over time (c) Comparison of baseline and peak (i.e. the maximal concentration of MUC5B detected during the infection for each individual) levels of MUC5B and between subjects with COPD and healthy subjects. (d) Correlation of peak MUC5B with peak concentrations of inflammatory cells and cytokines in sputum. (e) Correlation between peak sputum MUC5B and peak virus loads. (f) Correlation of peak MUC5B with peak change from baseline levels of the indicated antimicrobial peptides in sputum. (g) Correlation of peak sputum MUC5B with bacterial loads assessed by 16S quantitative PCR. (h) Correlation of peak MUC5B with peak respiratory tract symptom scores. (i) Correlation of peak sputum MUC5B with peak expiratory flow rate (PEF) change from baseline during exacerbation. In (c) individual datapoints shown, analysed by Wilcoxon matched-pairs signed rank test for baseline vs peak and Mann Witney U test for comparison of peak values between COPD and healthy subjects. **P<0.01. In (d) -(i), correlation analysis used was nonparametric (Spearman's correlation) performed on healthy volunteers and individuals with COPD pooled into a single group. In (g), 16S qPCR not measured in all patients due to lack of sample availability so data only shown where measured. 
SUPPLEMENTARY FIGURES
Visualization of mucin-associated DNA
Successful removal of DNA from MUC5AC was verified by electrophoretic separation of the mucin samples and subsequent visualization of associated DNA molecules via the DNAbinding dye SYBR Green I (S9430, Sigma Aldrich, St. Louis, MO, USA). Therefore, 40 µg of the mucin samples were mixed with Laemmli buffer, loaded on a polyacrylamide gel (Mini-Protean TGX Gels 4-20%, #45-1093, BioRad, Hercules, CA, USA) and separated (60 V for 10 min and 120 V until the dye front reached the end of the gel). The gel was stained using SYBR Green I afterwards (diluted 1:10.000 in TBE buffer) at room temperature under gentle shaking for 30 min. The DNA stain was visualized with a Gel Doc EZ Gel Documentation System (Biorad) with epi-illumination at a wavelength of 254 nm (Fig. 1) . We additionally confirmed that DNA was undetectable in samples of MUC5AC protein using Quant-iT PicoGreen dsDNA reagent (Invitrogen, Carlsbad, CA), according to the manufacturer's protocol, as previously described 8 . 
